TapImmune (NASDAQ:MRKR) and Bellicum Pharmaceuticals (NASDAQ:BLCM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Institutional & Insider Ownership
33.6% of TapImmune shares are owned by institutional investors. Comparatively, 54.9% of Bellicum Pharmaceuticals shares are owned by institutional investors. 23.7% of TapImmune shares are owned by insiders. Comparatively, 2.6% of Bellicum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares TapImmune and Bellicum Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bellicum Pharmaceuticals||$1.12 million||84.62||-$98.04 million||($2.44)||-0.84|
Bellicum Pharmaceuticals has higher revenue and earnings than TapImmune. TapImmune is trading at a lower price-to-earnings ratio than Bellicum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
TapImmune has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Comparatively, Bellicum Pharmaceuticals has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
This table compares TapImmune and Bellicum Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for TapImmune and Bellicum Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TapImmune presently has a consensus target price of $9.88, suggesting a potential upside of 76.07%. Bellicum Pharmaceuticals has a consensus target price of $18.50, suggesting a potential upside of 798.06%. Given Bellicum Pharmaceuticals’ higher possible upside, analysts clearly believe Bellicum Pharmaceuticals is more favorable than TapImmune.
TapImmune beats Bellicum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
TapImmune Company Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.